VRCA
Verrica Pharmaceuticals Inc.
Key Financials
Revenue
$35.6M
↑ 370.2%
Net Income
$-17886000
↑ 76.6%
Operating Income
$-12185000
↑ 81.5%
EPS (Diluted)
$-1.68
↓ 13.5%
Shareholders' Equity
$24.7M
↑ 350.9%
Total Assets
$47.1M
↓ 12.9%
Cash & Equivalents
$30.1M
↓ 34.9%
Total Liabilities
$22.4M
↓ 65.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-K | 3/11/2026 | View on SEC |
| 8-K | 3/11/2026 | View on SEC |
| SCHEDULE 13G/A | 2/17/2026 | View on SEC |
| 3/A | 2/2/2026 | View on SEC |
| SCHEDULE 13G/A | 1/29/2026 | View on SEC |
| 3 | 1/26/2026 | View on SEC |
| 4 | 12/30/2025 | View on SEC |
| SCHEDULE 13D/A | 12/30/2025 | View on SEC |
| 3 | 12/30/2025 | View on SEC |
| 3 | 12/30/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VRCA |
| Company Name | Verrica Pharmaceuticals Inc. |
| CIK | 1660334 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 484-453-3300 |